Importantly, the potent anti-tumor immunity promoted by T-VEC was further demonstrated to exhibit oncolytic properties and abscopal response in a murine cell line xenograft model with low stimulator of interferon genes (STING) expression, associated with resistance to anti-programmed cell death protein 1 (PD-1) immune checkpoint blockade [32]. The gene discussed is PDCD1; the disease is neoplasm.